295 related articles for article (PubMed ID: 26500059)
1. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.
Tigan AS; Bellutti F; Kollmann K; Tebb G; Sexl V
Oncogene; 2016 Jun; 35(24):3083-91. PubMed ID: 26500059
[TBL] [Abstract][Full Text] [Related]
2. Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.
Mayer IM; Doma E; Klampfl T; Prchal-Murphy M; Kollmann S; Schirripa A; Scheiblecker L; Zojer M; Kunowska N; Gebrail L; Shaw LE; Mann U; Farr A; Grausenburger R; Heller G; Zebedin-Brandl E; Farlik M; Malumbres M; Sexl V; Kollmann K
Blood; 2024 Apr; ():. PubMed ID: 38684032
[TBL] [Abstract][Full Text] [Related]
3. Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ; Beach D; Shapiro GI
Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
[TBL] [Abstract][Full Text] [Related]
4. The role of CDK6 in cancer.
Nebenfuehr S; Kollmann K; Sexl V
Int J Cancer; 2020 Dec; 147(11):2988-2995. PubMed ID: 32406095
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
[TBL] [Abstract][Full Text] [Related]
6. CDK6 coordinates
Uras IZ; Maurer B; Nivarthi H; Jodl P; Kollmann K; Prchal-Murphy M; Milosevic Feenstra JD; Zojer M; Lagger S; Grausenburger R; Grabner B; Holly R; Kavirayani A; Bock C; Gisslinger H; Valent P; Kralovics R; Sexl V
Blood; 2019 Apr; 133(15):1677-1690. PubMed ID: 30635286
[TBL] [Abstract][Full Text] [Related]
7. Scheicher R, Hoelbl-Kovacic A, Bellutti F, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
Blood; 2018 Aug; 132(9):978-979. PubMed ID: 30166363
[No Abstract] [Full Text] [Related]
8. CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Bellutti F; Tigan AS; Nebenfuehr S; Dolezal M; Zojer M; Grausenburger R; Hartenberger S; Kollmann S; Doma E; Prchal-Murphy M; Uras IZ; Höllein A; Neuberg DS; Ebert BL; Ringler A; Mueller AC; Loizou JI; Hinds PW; Vogl C; Heller G; Kubicek S; Zuber J; Malumbres M; Farlik M; Villunger A; Kollmann K; Sexl V
Cancer Discov; 2018 Jul; 8(7):884-897. PubMed ID: 29899063
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Goel S; DeCristo MJ; McAllister SS; Zhao JJ
Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
[TBL] [Abstract][Full Text] [Related]
10. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Antitumor Activity Evaluation of Artemisinin Bivalent Ligands.
Zhong H; Jiang Q; Wu C; Yu H; Li B; Zhou X; Fu R; Wang W; Sheng W
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257322
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action.
Golmohammadi M; Zamanian MY; Jalal SM; Noraldeen SAM; Ramírez-Coronel AA; Oudaha KH; Obaid RF; Almulla AF; Bazmandegan G; Kamiab Z
Food Sci Nutr; 2023 Dec; 11(12):7458-7468. PubMed ID: 38107139
[TBL] [Abstract][Full Text] [Related]
13. Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data.
Villa F; Crippa A; Pelizzoni D; Ardizzoia A; Scartabellati G; Corbetta C; Cipriani E; Lavitrano M; Ardizzoia A
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833875
[TBL] [Abstract][Full Text] [Related]
14. A C/ebpα isoform specific differentiation program in immortalized myelocytes.
Garcia-Cuellar MP; Akan S; Slany RK
Leukemia; 2023 Sep; 37(9):1850-1859. PubMed ID: 37532789
[TBL] [Abstract][Full Text] [Related]
15. The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer.
Zhou W; Wang W; Liang Y; Jiang R; Qiu F; Shao X; Liu Y; Fang L; Ni M; Yu C; Zhao Y; Huang W; Li J; Donovan MJ; Wang L; Ni J; Wang D; Fu T; Feng J; Wang X; Tan W; Fang X
Nat Commun; 2023 Jul; 14(1):4212. PubMed ID: 37452037
[TBL] [Abstract][Full Text] [Related]
16. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
Shu Y; Wang L; Ding Y; Zhang Q
Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
[TBL] [Abstract][Full Text] [Related]
17. Role and mechanism of Circ-PDE7B in the formation of keloid.
Tang Y; Li X
Int Wound J; 2023 Nov; 20(9):3738-3749. PubMed ID: 37291755
[TBL] [Abstract][Full Text] [Related]
18. Interactions between genes altered during cardiotoxicity and neurotoxicity in zebrafish revealed using induced network modules analysis.
Agarwal M; Sharma A; Kagoo R A; Bhargava A
Sci Rep; 2023 Apr; 13(1):6257. PubMed ID: 37069190
[TBL] [Abstract][Full Text] [Related]
19. C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis.
Huang S; Li J; Wu S; Zheng Z; Wang C; Li H; Zhao L; Zhang X; Huang H; Huang C; Xie Q
Oncogene; 2023 Apr; 42(17):1333-1346. PubMed ID: 36882524
[TBL] [Abstract][Full Text] [Related]
20. Protein Phosphorylation Alterations in Myotonic Dystrophy Type 1: A Systematic Review.
Costa A; Cruz AC; Martins F; Rebelo S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
